Phase 1 mRNA HIV Vaccine Trials

A breakdown of current HIV mRNA trials and a primer on the basics of mRNA technology.

Experimental mRNA-based Preventive HIV Vaccine Phase 1 Trials

The NIH announced a new study to test three mRNA-based HIV vaccine candidates. This study follows an announcement in January from IAVI about another mRNA-based HIV vaccine study. This snapshot compares the two studies.

Advocate, Translate, Catalyze: For HIV prevention and health equity

In this document, we look at the actions we are taking and those that as a field we all need to take to transform prevention “options” developed through research into prevention “choices” for people that can save lives and help end epidemics. This work is critical, and it is shared – just as we developed our strategic plan and EDI statement in partnership with so many, so too will we move this work forward, together.

AVAC’s Strategic Plan 2022-2026

AVAC’s strategic framework is grounded in a multi-layered approach that carefully considers all of the components needed to achieve the organization’s vision, capitalize on its key strengths, and ensure that AVAC is poised to make an impact on the issues it cares most about over the next five years, and beyond.

The vision describes the world we are striving for. The mission describes what AVAC does in service to achieving this vision. The strategic pillars outline the objectives and approaches that AVAC will take over the next five years to achieve its mission and vision. The strategic pillars are supported by AVAC’s core values—the principles by which we work—as well as a set of key enablers.

Calling on the Biden Administration to Scale Up mRNA Vaccine Manufacturing Capacity

This joint letter calls on the Biden Administration to rapidly scale up mRNA vaccine manufacturing capacity to reach approximately 4 billion people by the end of 2021.

HIV Vaccine Research: Building on the Lessons from COVID

Building on the lessons of COVID, HIV vaccine advocates can mobilize for an HIV vaccine research and access agenda. This two-page document gives suggested messaging.

Breaking the Bottlenecks to COVID-19 Vaccine Access

This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.

Essential Principles & Practices for GPP Compliance: Engaging stakeholders in biomedical research during the era of COVID-19

This document is a new tool to help guide stakeholder engagement in COVID-19 research. Built from the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP), this document responds to needs expressed by both researchers and advocates as the world watched COVID-19 research progress with unprecedented speed and urgency.

COVID Vax Tracker

The COVID Vax Tracker provides updates on COVID-19 vaccine trials worldwide. The downloadable tracker provides data on trial location, recruitment status, participant totals, inclusion criteria and more.

COVID-19 Vaccine Cheat Sheet: Access Edition

This two-pager profiles authorized vaccines with an emphasis on the “3 C’s” that have a significant impact on equitable access: cost, cold chain and manufacturing capacity.